Short- and long-term effects of a novel paclitaxel coated stent in the porcine coronary model

Clinical Research in Cardiology

Volumn 97, Issue 2, 2008, Pages 118-123

  Scheller, Bruno ^a   Kühler, Michael ^b   Cremers, Bodo ^a   Mahnkopf, Dirk ^c   Böhm, Michael ^a   Boxberger, Michael ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b BBraun Vascular Systems   (Germany)

^c IMTM GmbH   (Germany)

Author keywords

Drug eluting stent; Paclitaxel; Procine coronary model; Restenosis

Indexed keywords

'TAXUS'; COROFLEX; PACLITAXEL; POLYMER; POLYSULFONE; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BIOCOMPATIBILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DOMESTIC PIG; DRUG COATING; DRUG EFFECT; DRUG ELUTING STENT; DRUG SAFETY; EXPERIMENTAL MODEL; FOLLOW UP; HISTOLOGY; INFLAMMATION; INTIMA; MATERIAL COATING; NONHUMAN; PACLITAXEL ELUTING STENT; TREATMENT DURATION;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; PACLITAXEL; PROBABILITY; RANDOM ALLOCATION; RISK FACTORS; SURVIVAL RATE; SWINE; SWINE, MINIATURE; TIME FACTORS; TREATMENT OUTCOME;

EID: 39149104987     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-007-0597-6     Document Type: Article

References (19)

1. Axel DI, Kunert W, Goggelmann C, et al. (1997) Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96:636-645
2. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R (2004) Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 63:617-624
3. Creel CJ, Lovich MA, Edelman ER (2000) Arterial paclitaxel distribution and deposition. Circ Res 86:879-884
4. Farb A, Heller PF, Shroff S, et al. (2001) Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104:473-479
5. Heldman AW, Cheng L, Jenkins GM, et al. (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103:2289-2295
6. Herdeg C, Oberhoff M, Baumbach A, et al. (2000) Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 35:1969-1976
7. Kornowski R, Hong MK, Tio FO, et al. (1998) In-stent restenosis contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 31:224-230
8. Oberhoff M, Kunert W, Herdeg C, et al. (2001) Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter. Basic Res Cardiol 96:275-282
9. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004-1014
10. Scheller B, Grandt A, Wnendt S, Kuttler B, Bolz U, Lorenz G, Böhm M, Nickenig G (2005) Comparative study of tacrolimus and paclitaxel stent coating to prevent restenosis after coronary intervention. Z Kardiol 94:445-452
11. Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G (2004) Paclitaxel balloon coating-a novel method for prevention and therapy of restenosis. Circulation 110:810-814
12. Scheller B, Speck U, Romeike B, et al. (2003) Contrast media as a carrier for local drug delivery: successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 24:1462-1467
13. Scheller B, Speck U, Schmitt A, Böhm M, Nickenig G (2003) Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 42:1415-1420
14. Schwartz RS, Chronos NA, Virmani R (2004) Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 44:1373-1385
15. Schwartz RS, Huber KC, Murphy JG, et al. (1992) Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 19:267-274
16. Suzuki T, Kopia G, Hayashi S, et al. (2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188-1193
17. Unverdorben M, Degenhardt R, Vallbracht C, Wiemer M, Horstkotte D, Schneider H, Nienaber C, Bocksch W, Gross M, Boxberger M (2006) The paclitaxel-eluting Coroflextrade mark please stent pilot study (PECOPS I): acute and 6-month clinical and angiographic follow-up. Catheter Cardiovasc Interv 67:703-710
18. Unverdorben M, Degenhardt R, Wiemer M, Horstkotte D, Schneider H, Nienaber C, Bocksch W, Gross M, Boxberger M, Vallbracht C, for the PECOPS I Investigators (2007) The Paclitaxel-Eluting Coroflextrade mark Please Stent Pilot Study (PECOPS I): The 1-year clinical follow-up. Clin Res Cardiol 96(11):803-811
19. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. (1996) Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94:1690-1697